VIENNA, AUSTRIA, May 23, 2009 – RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced it has received the first European order for its Sequence Enrichment Solution from ATLAS Biolabs GmbH of Berlin, Germany, a leading genomic services provider.
In an announcement at the European Society of Human Genetics (ESHG) Conference 2009, the company said ATLAS Biolabs’ purchase includes the RDT 1000 system, PCR primer libraries, consumables kits, and training services.
“ATLAS Biolabs is a renowned genomic services provider with an esteemed scientific team that is highly respected in the European research community,” said Christopher McNary, President and Chief Executive Officer, RainDance Technologies. “We look forward to supporting their requirements with a solution that can dramatically enhance their genomic research services portfolio.”
McNary said the sale represents a key addition to the company’s global service provider network. “With our Sequence Enrichment Solution in place at ATLAS Biolabs, European researchers will have immediate access to our technology. It will enable scientists to perform high-resolution analysis of genetic variation between individuals within populations at a level unmatched by current methodologies,” he said.
“Our customers now are exploring the contribution of rare variants in their study of disease and are adopting targeted genomic sequencing methods to study large populations in this context. RainDance’s massively parallel microdroplet PCR-based solution for sequence enrichment is superior to all others available in the market because it is less prone to the selection bias associated with targeted sequencing,” said Dr. Peter Nürnberg, Co-Founder and Chief Executive Officer, ATLAS Biolabs. “Using the RainDance technology, we can amplify up to 4000 amplicons in a single PCR process with essentially no allelic amplification bias and a near 100% success rate of PCR primer pairs.”
Nürnberg said ATLAS Biolabs is discussing the RainDance Sequence Enrichment Solution with key customers and will invite them to perform proof-of-principle experiments once the instrument is installed. “We are pleased to be the first in Europe to offer this innovative approach and will work with RainDance to explore additional applications for their promising new technology.”
RainDance will immediately begin designing custom DNA primer libraries for ATLAS Biolabs’ customers and anticipates shipping the RDT 1000 system by July 2009.
“The first sale of our Sequence Enrichment Solution in Europe is a major step in our company’s growth,” said McNary. “Our technology is generating considerable interest in the region, and we anticipate announcing additional sales to leading European genomic and medical research centers in the coming weeks.”
About RainDance Technologies
RainDance Technologies is pioneering the use of high-throughput microdroplet-based analysis in human health and life science research. The company’s core RainStorm™ technology generates millions of discrete droplets that can encapsulate a single molecule, cell or reaction and be digitally analyzed and sorted one at a time. The power, precision and simplicity of microdroplets enable researchers to answer complex questions with unprecedented sensitivity and quantitation. The complete RainDance solution includes automated instrumentation, customizable bioinformatics and high-value consumables and reagents for applications including targeted next-generation DNA sequencing, methylation, digital PCR and single cell analysis. Based in Lexington, Massachusetts, the company supports scientists around the world through its international sales and support operations and a global network of distributors and service providers. For more information, please visit www.RainDanceTech.com.
RainDance, RainStorm, ThunderStorm, Digital Biology are trademarks of RainDance Technologies, Inc. All other brands may be trademarks of their respective holders.
About ATLAS Biolabs
ATLAS Biolabs GmbH is a leading provider of microarray-based genomic services such as genome-wide gene expression and SNP analyses, CGH analyses, and diagnostic services for registered doctors and hospitals, as well as for pharmaceutical, biotechnological, and diagnostic enterprises. The company is based in Berlin and Cologne, Germany.